Melvyn Lynn

Summary

Affiliation: Eisai Medical Research
Country: USA

Publications

  1. ncbi request reprint Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
    Melvyn Lynn
    Eisai Medical Research, Teaneck, New Jersey 07666 6741, USA
    J Infect Dis 187:631-9. 2003
  2. ncbi request reprint Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]
    Melvyn Lynn
    Eisai Medical Research Inc, Glenpointe Centre West, Teaneck, New Jersey 07666 6741, USA
    J Pharmacol Exp Ther 308:175-81. 2004
  3. doi request reprint Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
    Daniel P Rossignol
    Eisai Medical Research Inc, Ridgefield Park, New Jersey 07660, USA
    Innate Immun 14:383-94. 2008
  4. pmc Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers
    Daniel P Rossignol
    Eisai Medical Research, Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    Antimicrob Agents Chemother 48:3233-40. 2004
  5. ncbi request reprint Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
    Daniel P Rossignol
    Eisai Medical Research Inc, Teaneck, New Jersey 07666, USA
    J Endotoxin Res 8:483-8. 2002
  6. ncbi request reprint TLR4 antagonists for endotoxemia and beyond
    Daniel P Rossignol
    Eisai Medical Research Inc, NJ 07660, USA
    Curr Opin Investig Drugs 6:496-502. 2005
  7. pmc Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
    Antimicrob Agents Chemother 47:2796-803. 2003
  8. ncbi request reprint Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study
    Y Nancy Wong
    Eisai Research Institute, 1 Corporate Drive, Andover, MA 01810, USA
    J Clin Pharmacol 43:735-42. 2003
  9. ncbi request reprint Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531
    Anand Kumar
    Section of Critical Care Medicine, Health Sciences Centre, GE706, 820 Sherbrook St, Winnipeg, MB, Canada, R3A 1R9
    Chest 126:860-7. 2004
  10. ncbi request reprint Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Pharm Res 25:176-82. 2008

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
    Melvyn Lynn
    Eisai Medical Research, Teaneck, New Jersey 07666 6741, USA
    J Infect Dis 187:631-9. 2003
    ..01). These results demonstrate that E5564 blocks the effects of LPS in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis...
  2. ncbi request reprint Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]
    Melvyn Lynn
    Eisai Medical Research Inc, Glenpointe Centre West, Teaneck, New Jersey 07666 6741, USA
    J Pharmacol Exp Ther 308:175-81. 2004
    ..No differences were observed. These results demonstrate that E5564 blocks the effects of endotoxin in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis...
  3. doi request reprint Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
    Daniel P Rossignol
    Eisai Medical Research Inc, Ridgefield Park, New Jersey 07660, USA
    Innate Immun 14:383-94. 2008
    ..The objective of this study was to assess the safety, and pharmacokinetic and pharmacodynamic profile of E5564 infused twice-daily at three target steady-state plasma levels of approximately 1, 3 and 10 microg/ml in healthy volunteers...
  4. pmc Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers
    Daniel P Rossignol
    Eisai Medical Research, Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    Antimicrob Agents Chemother 48:3233-40. 2004
    ....
  5. ncbi request reprint Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
    Daniel P Rossignol
    Eisai Medical Research Inc, Teaneck, New Jersey 07666, USA
    J Endotoxin Res 8:483-8. 2002
    ..Results from these multiple-dose studies indicate that under these conditions of administration, plasma levels of E5564 can be predictive of long-term pharmacodynamic activity...
  6. ncbi request reprint TLR4 antagonists for endotoxemia and beyond
    Daniel P Rossignol
    Eisai Medical Research Inc, NJ 07660, USA
    Curr Opin Investig Drugs 6:496-502. 2005
    ..This review discusses current, preclinical and clinical research regarding eritoran (E-5564), an analog of the non-toxic lipid A from Rhodobacter sphaeroides, as well as other antagonists of TLR4 in a variety of diseases...
  7. pmc Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
    Antimicrob Agents Chemother 47:2796-803. 2003
    ..Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles...
  8. ncbi request reprint Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study
    Y Nancy Wong
    Eisai Research Institute, 1 Corporate Drive, Andover, MA 01810, USA
    J Clin Pharmacol 43:735-42. 2003
    ..E5564 lacked LPS-like agonist activity at doses up to 3.5 mg. Taken together, we believe that E5564 is a safe, potent antagonist of LPS in blood and will likely benefit patients in the treatment of LPS-related diseases...
  9. ncbi request reprint Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531
    Anand Kumar
    Section of Critical Care Medicine, Health Sciences Centre, GE706, 820 Sherbrook St, Winnipeg, MB, Canada, R3A 1R9
    Chest 126:860-7. 2004
    ....
  10. ncbi request reprint Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits
    Kishor M Wasan
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Pharm Res 25:176-82. 2008
    ..This was done with eritoran administered as stable micelle formulations of mean hydrodynamic diameters of 8 or 27 nm)...
  11. ncbi request reprint Elevated plasma levels of limulus amoebocyte lysate-reactive material
    Daniel Rossignol
    J Infect Dis 194:1340; author reply 1340-1. 2006